Cero Therapeutics Holdings DEF 14A Filing
Ticker: CEROW · Form: DEF 14A · Filed: Aug 26, 2024 · CIK: 1870404
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Cero Therapeutics proxy filed - vote on Sept 12th for company direction.
AI Summary
Cero Therapeutics Holdings, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 26, 2024, for its annual meeting on September 12, 2024. The company, formerly known as Phoenix Biotech Acquisition Corp., is seeking shareholder approval for matters related to its corporate governance and operations. The filing details executive compensation, director elections, and other proposals requiring shareholder votes.
Why It Matters
This filing is crucial for shareholders as it outlines the proposals they will vote on at the upcoming annual meeting, impacting the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing for an annual meeting, not indicating immediate financial distress or significant new risks.
Key Numbers
- 20240912 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20240826 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- PHOENIX BIOTECH ACQUISITION CORP. (company) — Former Company Name
- 20240912 (date) — Meeting Date
- 20240826 (date) — Filing Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information and solicit their votes for the annual meeting scheduled for September 12, 2024.
When is the annual meeting of Cero Therapeutics Holdings, Inc. scheduled?
The annual meeting is scheduled for September 12, 2024.
What was Cero Therapeutics Holdings, Inc. formerly known as?
Cero Therapeutics Holdings, Inc. was formerly known as Phoenix Biotech Acquisition Corp.
On what date was this Definitive Proxy Statement filed?
This Definitive Proxy Statement was filed on August 26, 2024.
What is the company's business address?
The company's business address is 201 Haskins Way, Suite 230, South San Francisco, CA 94080.
Filing Stats: 4,516 words · 18 min read · ~15 pages · Grade level 14.4 · Accepted 2024-08-26 17:15:48
Key Financial Figures
- $0.0001 — g shares of our common stock, par value $0.0001 per share (“Common Stock”)
Filing Documents
- ea0212105-def14a_cerothera.htm (DEF 14A) — 346KB
- image_001.jpg (GRAPHIC) — 3KB
- image_002.jpg (GRAPHIC) — 296KB
- image_003.jpg (GRAPHIC) — 273KB
- 0001213900-24-072636.txt ( ) — 1071KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 PROPOSAL NO. 1: REVERSE STOCK SPLIT PROPOSAL 10 PROPOSAL NO. 2: ADJOURNMENT PROPOSAL 18
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 19 STOCKHOLDER PROPOSALS 30 STOCKHOLDER COMMUNICATIONS 30 HOUSEHOLDING 30 SOLICITATION OF PROXIES 31 ANNUAL REPORT 31 OTHER MATTERS 31 WHERE YOU CAN FIND ADDITIONAL INFORMATION 31 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement (this “proxy statement”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this proxy statement, including statements regarding the Company’s future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development (“R&D”) costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions. Fo